Status:
UNKNOWN
Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)
Lead Sponsor:
Assiut University
Conditions:
Ophthalmopathy
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
To compare the clinical effectiveness of ranibizumab and combination of ranibizumab and triamcinolone for the treatment of macular oedema secondary to CRVO
Eligibility Criteria
Inclusion
- Patients 18 years of age or older with visual impairment resulting from macular edema secondary to CRVO.
- A BCVA approximate Snellen equivalents, 20/40.
Exclusion
- Use of intra-vitreal anti-VEGF injections 3 months or less before baseline.
- Pan-retinal laser photocoagulation 3 months or less before baseline,
- Topical ocular or systemic corticosteroids administered for 30 consecutive days.
- Intraocular or periocular corticosteroid use 3 months or less before screening (study eye),
- Use of intraocular corticosteroid implants,
- Uncontrolled glaucoma (intraocular pressure \[IOP\] 30 mmHg with medication) at the time of screening or baseline,
- iris neovascularization or neo-vascular glaucoma.
Key Trial Info
Start Date :
May 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04460001
Start Date
May 16 2019
End Date
December 1 2021
Last Update
July 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wael
Asyut, Egypt, 11711